01-projects/health-and-longevity

marchione peptides 101

2026-05-11·reference·source: Max Marchione (X long-form note + TBPN "Great Peptide Debate" with Martin Shkreli)·by Max Marchione

Peptides 101 - Max Marchione

Why this is in the vault

Founder shared on 2026-05-11. Slot is the peptide layer of the health-and-longevity project - a class of intervention the existing Attia / Sinclair synthesis notes barely cover. Attia is publicly conservative on peptides (no compelling RCTs at the doses people use them). Sinclair has walked back rapamycin + taurine but hasn't engaged much on the broader peptide category. Marchione is one of the loudest pro-peptide voices in the founder-influencer ecosystem and he's running a company that benefits if peptides go mainstream, so he's worth understanding precisely so we can pressure-test the bull case before the founder makes a protocol decision.

Maps to the project's open question #3 (rapamycin / NMN approach) and contributes evidence to the Candidate-C composite-outcome quarterly rotation: peptides are most defensibly slotted as a "specific biomarker is stuck" intervention, not a baseline-protocol layer.

The core content

Marchione's public canon on peptides spans an X long-form note (paywalled, 2026-05-11), a published TBPN "Great Peptide Debate" with Martin Shkreli, and recurring posts predicting peptides become the biggest consumer health category of 2026. Key claims, drawn from the TBPN transcript and adjacent public posts:

The peptides he names

In broader peptide community discourse he is also positively-aligned with MOTS-c (mitochondrial-derived peptide, claimed metabolic / endurance effects), CJC-1295 + Ipamorelin (GH-releasing stack), and Tesofensine (appetite suppression, dopamine-norepinephrine reuptake) - though these don't appear in the TBPN transcript verbatim.

Where to get them (his stance)

This is the load-bearing part of the position. Marchione publicly:

  1. Opposes pure gray-market sourcing from research-chems vendors that sell "for research use only" with no medical oversight - his position is "peptides aren't supplements and shouldn't be sourced online unsupervised."
  2. Advocates compounding pharmacies + physician oversight as the legal pathway. Most US compounding access depends on a physician prescription + a 503A/503B pharmacy. His own Superpower does not currently distribute unapproved peptides.
  3. Lobbies for FDA reclassification that would let DTC longevity companies distribute peptides under medical oversight at scale. This is the policy outcome that would let Superpower expand into the category.
  4. On Shkreli's pushback: Marchione concedes "we don't know whether it's placebo yet" for some peptides but argues thousands of physicians with licenses on the line using them for 10-20 years is a real-world safety signal worth more than the absence of large RCTs.

Safety, cycling, stacking

Disclosed conflicts

Superpower (his company) is positioned to be the distribution channel if peptide regulation loosens. His bullishness on the category is load-bearingly conflicted - he is not a neutral observer. Treat his framing the same way we'd treat a Sinclair Tru Niagen post or an Attia AG1 sponsor slot: useful as a primary source on the bull case, not as the consensus medical view.

Mapping against Ray Data Co

Protocol-design decision for the founder

Vendor evaluation framework

If the founder ever moves into peptides, the only acceptable sourcing chain is: licensed physician with longevity-medicine credentials → 503A compounding pharmacy → product with certificate of analysis. Specifically avoid: research-chem vendors, Telegram peptide groups, gray-market "for research only" labeling with retail consumer packaging. The Superpower-style DTC channel does not currently sell unapproved peptides and Marchione confirms this.

Targeting-systems thesis check

Marchione's bull case is substrate-positive for the project's framing: peptides are a new actuator class in the targeting-system. They're not a new sensor and they're not a new target. They're a high-specificity action that can hit a single biomarker (HbA1c via GLP-1, tendon healing via BPC-157) where lifestyle/supplement levers can't. That's the right way to slot them: as a Layer-3 (actions) tool reserved for specific biomarker-stuck cases, not as a baseline protocol.

The risk to flag explicitly: peptides have the same Goodhart-trap shape as biomarker chasing. A GLP-1 will move HbA1c and weight without necessarily improving the underlying functional-capability target (Centenarian Decathlon-style outcomes). Lean muscle loss on GLP-1s is the canonical example. The composite Candidate-C outcome target catches this; a biomarker-only Candidate B would miss it.

Founder-personal applicability

Cross-position against the project synthesis

This note is intentionally dissenting from Marchione's bullish framing because Attia's caution + the founder's RDCO-style preference for evidence-strong-before-novel maps better to his life stage (healthy 30-something, no acute condition). When/if the founder hits a stuck biomarker, this note becomes the input for "OK now we look harder at the peptide layer."

Related